BMY Share Price | Bristol Myers Squibb Co. Stock Analysis & Recommendation

Q: How big is Bristol Myers Squibb Co.?

Market Cap: As of Jun 18, Bristol Myers Squibb Co. has a market capitalization of 129,319.56 million, classifying it as a Large Cap company.Recent Quarterly Performance: For the latest four quarters, Bristol Myers Squibb Co. reported net sales of 47,636.00 million and a net profit of 5,437.00 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 16,335.00 million and total assets of 92,603.00 million.

Q: What does Bristol Myers Squibb Co. do?

Overview:Bristol Myers Squibb Co. is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products within the Pharmaceuticals & Biotechnology industry, classified as a large-cap company.Financial Snapshot:Most recent Net Sales: 11,201 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 2,462 Million (Quarterly Results - Mar 2025) Market cap: USD 129,319.56 Million (Large Cap)Key Metrics:P/E: 15.00 Dividend Yield: 78.83% Debt Equity: 2.19 Return on Equity: 49.65% Price to Book: 7.44Contact Details:Address: 430 E 29th St Fl 14, NEW YORK NY: 10016-8367 Tel: ['1 212 5464000', '1 609 2527509'] Fax: 1 302 6555049 Website: https://www.bms.com/

Q: Who are in the management team of Bristol Myers Squibb Co.?

As of March 2022, the management team of Bristol Myers Squibb Co. includes Dr. Giovanni Caforio, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, Dr. Vicki Sato holds the position of Lead Independent Director. The board also features several independent directors: Mr. Peter Arduini, Mr. Robert Bertolini, Mr. Michael Bonney, and Mr. Matthew Emmens.

Q: Is Bristol Myers Squibb Co. overvalued or undervalued?

As of 31 July 2025, the valuation grade for Bristol Myers Squibb Co. has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company appears to be undervalued, particularly when considering its P/E ratio of 15, which is significantly lower than the industry average, and its EV to EBITDA ratio of 9.01, which also suggests a favorable valuation relative to earnings before interest, taxes, depreciation, and amortization. Additionally, the company boasts a high ROE of 49.65%, reflecting strong profitability.In comparison to its peers, Bristol Myers Squibb Co. has a P/E ratio of 14.33, which is lower than Eli Lilly & Co. at 40.89 and Johnson & Johnson at 26.18, reinforcing its undervaluation. The company’s EV to EBITDA ratio of 9.01 is also more attractive than AbbVie, Inc. at 16.51. Despite the positive valuation metrics, Bristol Myers Squibb has underperformed the S&P 500 in recent periods, with a year-to-date return of -19.38% compared to the S&P 500's 12.22%, suggesting that the market may not fully recognize its value yet.

Q: Is Bristol Myers Squibb Co. technically bullish or bearish?

As of 31 October 2025, the technical trend for Bristol Myers Squibb Co. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, and the KST is bearish on both weekly and monthly time frames. The Bollinger Bands show a sideways trend weekly and bearish monthly. Dow Theory suggests a mildly bullish outlook on the weekly basis, but no trend on the monthly.In terms of performance, Bristol Myers Squibb has underperformed the S&P 500 across multiple periods, with a year-to-date return of -19.40% compared to the S&P 500's 16.30%, and a one-year return of -16.07% versus 19.89%. Overall, the current technical stance is mildly bearish, with mixed signals across different indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

9.69 M

Shareholding (Dec 2025)

FII

18.80%

Held by 589 FIIs

DII

47.13%

Held by 207 DIIs

Promoter

0.15%

How big is Bristol Myers Squibb Co.?

22-Jun-2025

As of Jun 18, Bristol Myers Squibb Co. has a market capitalization of $129.32 billion, with recent net sales of $47.64 billion and a net profit of $5.44 billion.

View full answer

What does Bristol Myers Squibb Co. do?

22-Jun-2025

Bristol Myers Squibb Co. is a large-cap biopharmaceutical company involved in the discovery, development, and sale of pharmaceutical products. As of March 2025, it reported net sales of $11.2 billion and a net profit of $2.5 billion.

View full answer

Who are in the management team of Bristol Myers Squibb Co.?

22-Jun-2025

As of March 2022, Bristol Myers Squibb Co.'s management team includes Dr. Giovanni Caforio as Chairman and CEO, and Dr. Vicki Sato as Lead Independent Director, along with independent directors Peter Arduini, Robert Bertolini, Michael Bonney, and Matthew Emmens.

View full answer

Is Bristol Myers Squibb Co. overvalued or undervalued?

20-Sep-2025

As of July 31, 2025, Bristol Myers Squibb Co. is considered very attractive due to its undervalued P/E ratio of 15, favorable EV to EBITDA ratio of 9.01, and high ROE of 49.65%, despite underperforming the S&P 500 with a year-to-date return of -19.38%.

View full answer

Is Bristol Myers Squibb Co. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Bristol Myers Squibb Co. shows a mildly bearish technical trend with mixed signals across indicators, underperforming the S&P 500 year-to-date by -19.40% compared to its 16.30% gain.

View full answer

Compare Bristol Myers Squibb Co. with Similar Stocks

Pfizer Inc.Merck & Co., Inc.AbbVie, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Healthy long term growth as Net Sales has grown by an annual rate of 6.47% and Operating profit at 23.31%

The company has declared positive results in Mar'2025 after 4 consecutive negative quarters

With ROCE of 19.69%, it has a fair valuation with a 3.08 Enterprise value to Capital Employed

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 166,176 Million (Large Cap)

P/E

13.00

Industry P/E

Dividend Yield

46.77%

Debt Equity

1.88

Return on Equity

65.61%

Price to Book

9.00

Revenue and Profits:

Net Sales:

12,502 Million

(Quarterly Results - Dec 2025)

Net Profit:

1,086 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

17.42%

6 Months

27.53%

1 Year

-4.72%

2 Years

11.79%

3 Years

-8.49%

4 Years

-12.12%

5 Years

-1.31%

Bristol Myers Squibb Co. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

2.83%

EBIT Growth (5y)

24.18%

EBIT to Interest (avg)

5.76

Debt to EBITDA (avg)

1.96

Net Debt to Equity (avg)

2.19

Sales to Capital Employed (avg)

0.73

Tax Ratio

10.99%

Dividend Payout Ratio

71.98%

Pledged Shares

Institutional Holding

82.46%

ROCE (avg)

13.51%

ROE (avg)

33.03%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

6.85

EV to EBIT

12.45

EV to EBITDA

8.19

EV to Capital Employed

2.92

EV to Sales

3.25

PEG Ratio

Dividend Yield

86.81%

ROCE (Latest)

23.42%

ROE (Latest)

51.19%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 219 Schemes (33.91%)

Foreign Institutions

Held by 589 Foreign Institutions (18.8%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "12,502.00",
          "val2": "12,222.00",
          "chgp": "2.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4,664.00",
          "val2": "4,871.00",
          "chgp": "-4.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "432.00",
          "val2": "480.00",
          "chgp": "-10.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2,467.00",
          "val2": "-1,078.00",
          "chgp": "-128.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,086.00",
          "val2": "2,195.00",
          "chgp": "-50.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "290.50%",
          "val2": "314.60%",
          "chgp": "-2.41%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -0.22% vs 7.32% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 178.99% vs -211.11% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "48,194.00",
          "val2": "48,300.00",
          "chgp": "-0.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "19,238.00",
          "val2": "19,309.00",
          "chgp": "-0.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1,891.00",
          "val2": "1,947.00",
          "chgp": "-2.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6,464.00",
          "val2": "-18,154.00",
          "chgp": "64.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "7,056.00",
          "val2": "-8,933.00",
          "chgp": "178.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "313.70%",
          "val2": "200.00%",
          "chgp": "11.37%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

12,502.00

12,222.00

2.29%

Operating Profit (PBDIT) excl Other Income

4,664.00

4,871.00

-4.25%

Interest

432.00

480.00

-10.00%

Exceptional Items

-2,467.00

-1,078.00

-128.85%

Consolidate Net Profit

1,086.00

2,195.00

-50.52%

Operating Profit Margin (Excl OI)

290.50%

314.60%

-2.41%

USD in Million.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Consolidated Net Profit

Not Applicable: The company has declared_date for only one period

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

48,194.00

48,300.00

-0.22%

Operating Profit (PBDIT) excl Other Income

19,238.00

19,309.00

-0.37%

Interest

1,891.00

1,947.00

-2.88%

Exceptional Items

-6,464.00

-18,154.00

64.39%

Consolidate Net Profit

7,056.00

-8,933.00

178.99%

Operating Profit Margin (Excl OI)

313.70%

200.00%

11.37%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -0.22% vs 7.32% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 178.99% vs -211.11% in Dec 2024

All Annual Results

Company CV

About Bristol Myers Squibb Co.

Bristol Myers Squibb Co.

Pharmaceuticals & Biotechnology

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.

Company Coordinates

Company Details

430 E 29th St Fl 14 , NEW YORK NY : 10016-8367

Tel: 1 212 54640001 609 2527509

https://www.bms.com/

Registrar Details